In silico study demonstrates high binding affinity and favorable ADMET profiles for novel pyrrolopyrazole derivatives, indicating strong drug candidate potential.
Novel 1,6a-dihydropyrrolo[3,4-c]pyrazole-4,6(3aH,5 H)-dione derivatives were synthesized via the reaction of hydrazonoyl bromides with N-arylmaleimides and subsequently oxidized to pyrrolo[3,4-c]pyrazole-4,6(1 H,5 H)-diones. Molecular docking against the target protein (PDB ID: 4N9S) revealed that compounds 3c and 4c exhibited the highest binding affinities (- 7.45 and - 7.31 kcal/mol, respectively), forming stable π-cation and hydrogen-bond interactions with key residues (Arg176, Glu259, Tyr257). Structure-activity relationship analysis indicated that electron-donating substituents enhanced the predicted biological activity. In silico ADMET profiling demonstrated 100% intestinal absorption, favorable distribution, and absence of toxicity, confirming the compounds' potential as promising therapeutic leads.
No takes yet. Share an insight, caveat, or question.
Zaki et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: